Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

170
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
170
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

8.5K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

160
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
160

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acuphagia with sequential ingestion of sharp metallic objects and a magnet, causing intestinal bezoar, perforation, and peritonitis: a case report.

International journal of surgery case reports·2026
Same author

In-hospital outcomes of acute coronary syndrome in patients with cancer: a systematic review and meta-analysis.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis.

Biomedicines·2026
Same author

Cardiovascular Outcomes with Colchicine in Coronary Artery Disease and HFpEF: A Propensity-Matched TriNetX Analysis.

Journal of cardiovascular development and disease·2026
Same author

Existence of gender bias in clinical dentistry: A cross-sectional study on Perception and experience of dental clinicians at a private dental institute in Lahore.

Pakistan journal of medical sciences·2026
Same author

Harnessing Tolypothrix sp. A-8 for biogenic synthesis of silver oxide nanoparticles (AgONPs) for multifunctional biomedical applications.

Discover nano·2026

Related Experiment Video

Updated: Jun 29, 2025

Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

54.9K

Checkpoint Inhibitor-Related Capillary Leak Syndrome (CLS).

Ahmad Raja1, Amrat Kumar1, Muhammad Abdullah2

  • 1Internal Medicine, Bassett Medical Center, Cooperstown, USA.

Cureus
|April 8, 2024
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICIs) can cause rare capillary leak syndrome (CLS), a serious side effect. Early recognition and treatment with steroids are crucial for managing this ICI-induced condition.

Keywords:
generalized anasarcaimmune checkpoint inhibitorsimmune-related adverse event (irae)immunotherapysystemic capillary leak syndrome

More Related Videos

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

392
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K

Related Experiment Videos

Last Updated: Jun 29, 2025

Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

54.9K
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

392
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Immune checkpoint inhibitors (ICIs) are vital cancer therapies.
  • ICI treatment can lead to immune system overactivation and unique side effects.
  • Recognizing these side effects is critical for patient management.

Observation:

  • Capillary leak syndrome (CLS) is a rare but severe adverse event associated with ICIs.
  • CLS involves increased capillary permeability, causing plasma leakage.
  • Clinical signs include edema, hypotension, hypoalbuminemia, and hemoconcentration.

Findings:

  • CLS is a potentially life-threatening consequence of ICI therapy.
  • Prompt identification and cessation of the causative immunotherapy are essential.
  • Supportive care and immunosuppressants, like steroids, form the primary treatment strategy.

Implications:

  • Understanding ICI-induced CLS improves patient outcomes.
  • Awareness aids clinicians in timely diagnosis and intervention.
  • Management strategies focus on mitigating immune overactivation and supporting vascular integrity.